Haemophilus influenzae type b (HIB) is the most commiion cause of bacterial meningitis in children. Conventional antibiotic therapy for this disease is ampicillin plus chloram- phenicol. Approximately 20% of HIB strains in the United States are currently resistant to ampicillin (5, 6, 13) . Chloramphenicol, the alternative drug, has potential bone marrow toxicity, and resistance of HIB strains to this drug has been reported recently (7, 8, 10, 15, 19) . In Bangkok, Salmonella strains, a relatively common cause of meningitis in early infancy, have also been found to be resistant to ampicillin, chloramphenicol, co-trimoxazole, and all available aminoglycosides.
Cefuroxime is a second-generation cephalosporin which is resistant to inactivation by many beta-lactamases. It is active in vitro against HIB strains, Streptococcus pneumoniae, and Neisseria meningitidis (9) , the three most common causes of bacterial meningitis in infants and children. It is also active against many gram-negative enteric bacilli, including Salmonella strains (9) . Successful treatment of bacterial meningitis in children with cefuroxime was recently reported (14, 17) . The causative agents in these studies included HIB, S. pneumoniae, and N. meningitidis, but there were no ampicillin-and chloramphenicol-resistant HIB or Salmonella strains.
We report here our experience with cefuroxime for the treatment of bacterial meningitis in seven infants and childrvn, among whom were four patients with ampicillin-and chloramphenicol-resistant HIB infections and one infant with a multiply-resistant Salmonella sp. infection. We measured the concentration of cefuroxime in cerebrospinal fluid (CSF) samples from 15 children who had meningitis and 10 children who did not have meningitis.
MATERIALS AND METHODS
Patients. The patients in this study included 15 15 months to 2 years after recuperation from meningitis, whereas both children who were initially treated ineffectively with ampicillin and chloramphenicol for 2 weeks were severely brain damaged.
Of the two patients infected with Salmonella strains, one was a 2.5-month-old girl whose CSF and blood cultures grew a multiply-resistant strain of S. krefeld. Therapy with cefuroxime was started after she had already developed ventriculitis. She improved gradually with a regimen of cefuroxime given intravenously (200 mg/kg per day) and intraventricularly (5 mg daily for 4 days). Fever disappeared and ventricular fluid was sterile after 72 h of treatment. Intravenous therapy was continued for 21 days, and she had an uneventful recovery and was considered normal at age 2.5 years.
The other patient was a 25-day-old girl with S. typhimurium meningitis. Initial treatment consisted of cefuroxime, gentamicin, and co-trimoxazole. Gentamicin and co-trimoxazole were discontinued after 2.5 days when the isolate was shown to be susceptible to cefuroxime. A culture of CSF taken on that day still grew a few S. typhimurium colonies. She became afebrile and was considered clinically normal on day 4 of treatment, at which time the CSF culture was sterile. Therapy with 250 mg of cefuroxime per kg per day was continued for 21 days.
One of the seven cefuroxime-treated patients had high fever followed by a generalized maculopapular rash on day 18 of treatment, which disappeared within 24 h, after discontinuation of cefuroxime treatment.
Cefuroxime penetration into CSF and subdural fluid. The concentrations of cefuroxime in CSF and serum at 2 h after a 50-mg/kg dose given by rapid intravenous infusion are shown in Table 1 . All CSF specimens had less than 100 erythrocytes per ml. The cefuroxime concentrations in the CSF of the two patients who were severely brain damaged were 14.6 and 17.6 ,ug/ml on day 2 and 8.7 and 9.6 ,ug/ml on day 14. These concentrations were exceptionally high due to greater than usual brain damage, so the figures were not included for statistical calculation.
Cefuroxime concentrations in subduiral fluid were measured in 12 specimens, 4 from each of three patients who had HIB meningitis. The cefuroxime concentration in each of these patients was 12.6, 15, and 25.2 ,ug/ml.
DISCUSSION
The data from the present study are consistent with those of previous studies showing good correlation between the concentration of cefuroxime in the CSF and the degree of meningeal inflammation (12, 14) . The cefuroxime concentration in the CSF at 2 h after the dose on day 2 of treatment was comparable to that reported by Pfenninger et al. (14) using the same dosage 7.0 ± 1.0 ,ug/ml. These levels exceed 7 .0 ,ug/ml) were also larger than the MICs for HIB, S. pneumoniae, and N. meningitidis but not for Salmonella strains. The concentrations and penetration of cefuroxime in the CSF of patients without meningitis were one-third to one-sixth of those in purulent CSF. Del Rio et al. (6) reported concentrations of cefuroxime in CSF at 0.5 to 4 h after a single dose of 50 mg/kg was given to children with purulent meningitis of 3.03 ± 2.5 ,ug/ml (mean ± standard deviation).
Among the second-generation cephalosporins, cefuroxime and cefamandole have comparable in vitro activity against HIB meningitis and better activity than cefoxitin has (9) . Treatment failures of HIB meningitis with cefamandole (150 to 200 mg/kg per day) have been reported (1, 16) and are believed to be due to the instability of cefamandole to the Haemophilus beta-lactamase (1, 16, 18) . McCracken and coworkers (11) showed that cefuroxime was relatively ineffective in experimental meningitis compared with chloramphenicol, cefoperazone, ceftriaxone, or moxalactam. On the other hand, controlled studies demonstrated that cefuroxime was comparable to ampicillin and chloramphenicol in treating childhood meningitis caused by the three most common organisms (14, 17) . There have been no reports of failure in the therapy of meningitis with appropriate dosages of cefuroxime. In addition we report the effectiveness of cefuroxime for treatment of meningitis caused by ampicillin-and chloramphenicol-resistant HIB and Salmonella strains.
In conclusion, we recommend a dosage of 200 mg of cefuroxime per kg per day given intravenously in four divided doses for therapy of HIB meningitis. Although the two patients with Salmonella meningitis were successfully treated with 200 mg/kg per day plus 5 mg given intraventricularly for 4 days in one case and 250 mg/kg per day in the other, the most appropriate regimen for salmonella meningitis has not been considered.
